CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE

$0M01FY2000RRNIH

University Of Wisconsin Madison, Madison WI

Investigators

Linked publications & trials

Paper 36946148 Paper 36940238 Paper 36066606 Paper 33471392 Paper 33252918 Paper 32795586 Paper 30160050 Paper 29251951 Paper 29025889 Paper 28862877 Paper 28125291 Paper 27613925 Paper 27609657 Paper 27489874 Paper 27061252 Paper 27001469 Paper 26227019 Paper 26012360 Paper 25979524 Paper 25918834 Paper 25783161 Paper 25744958 Paper 25485413 Paper 25384069 Paper 25360868 Paper 25091879 Paper 24952994 Paper 24835502 Paper 24711627 Paper 24642450 Paper 24589344 Paper 24556849 Paper 24529411 Paper 24498897 Paper 24364404 Paper 24332222 Paper 24209888 Paper 24187656 Paper 24142237 Paper 24084071 Paper 24050723 Paper 23975881 Paper 23954071 Paper 23855693 Paper 23844029 Paper 23780705 Paper 23669872 Paper 23669301 Paper 23632943 Paper 23612440 Paper 23541324 Paper 23537892 Paper 23508266 Paper 23414537 Paper 23410621 Paper 23341886 Paper 23331564 Paper 23297788 Paper 23287844 Paper 23181791 Paper 23169798 Paper 23041173 Paper 23040888 Paper 22995766 Paper 22963593 Paper 22865499 Paper 22832325 Paper 22818728 Paper 22766097 Paper 22750539 Paper 22735035 Paper 22694930 Paper 22642839 Paper 22588883 Paper 22554704 Paper 22321809 Paper 22241742 Paper 22236729 Paper 22227382 Paper 22180577 Paper 22160762 Paper 22140356 Paper 22103958 Paper 22102290 Paper 22095547 Paper 22070912 Paper 21991891 Paper 21960534 Paper 21878241 Paper 21798578 Paper 21792658 Paper 21699476 Paper 21572527 Paper 21496892 Paper 21441381 Paper 21416234 Paper 21397937 Paper 21373381 Paper 21347742 Paper 21335259

Abstract

This study is an efficient Phase III trial designed to prevent skin cancers using a-difluoromethylornithine (DFMO). DFMO is a chemopreventive agent that inhibits the promotion and early progression of many animal epithelial and skin cancers. However, DFMO has not been subjected to a pivotal controlled Phase III trial. Prior studies by University of Wisconsin investigators have shown that DFMO can be safely given to human subjects and that it inhibits skin ornithine decarboxylase (ODC), induced in vitro by the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Our primary hypothesis is: Will subjects with a prior history of one or more skin cancers taking DFMO for average of four years have a decrease in the rate of new skin cancers as compared to placebo controls? Our secondary hypotheses are: Will TPA-induced ODC inhibition be validated as an intermediary marker for DFMO as a chemoprevention agent? Will inhibition of polyamine levels in the skin of subjects on DFMO be validated as an intermediary marker for DFMO as a chemoprevention agent? Will DFMO administration be acceptable over the 3-5 years of treatment?

View original record on NIH RePORTER →